Background: Recent epidemiological evidence indicates an association between cardiovascular diseases and pulmonary fibrosis. The vascular endothelium acts to maintain vascular homeostasis through multiple mechanisms and impaired endothelial function can contribute to the development, progression and clinical expression of atherosclerosis.
Introduction
A growing body of epidemiological evidence indicates an association between cardiovascular diseases and pulmonary fibrosis. [1] [2] [3] [4] Although most deaths in idiopathic pulmonary fibrosis (IPF) are due to a respiratory cause, cardiovascular events are also reported to be an important cause of mortality. 5, 6 There are several possible mechanisms linking pulmonary fibrosis to cardiovascular disease. For example, several cytokines including interleukin-1β (IL-1β), IL-8, tumor necrosis factor-α (TNF-α) and intercellular adhesion molecule-1 (ICAM-1), all of which have been reported to be involved in the pathogenesis of pulmonary fibrosis, [7] [8] [9] also play a key role in the process of atherosclerosis. 10 In addition, the clotting cascade is activated in pulmonary fibrosis and has been implicated in its pathogenesis. 11 Furthermore, chronic hypoxic stress, to which patients with pulmonary fibrosis are often exposed, results in irreversible remodeling of the vasculature and surrounding tissues, characterized by smooth muscles proliferation and fibrosis. 12 The vascular endothelium acts to maintain vascular homeostasis through multiple mechanisms, and alteration in its function precedes the development of morphological atherosclerotic changes. 13 Endothelial dysfunction results in impaired regulation of vascular tone, a prothrombotic state, and increased production of inflammatory Page 6 / 25 cytokines and adhesion molecules, and hence, it is associated with the risk of future cardiovascular events. 13 Endothelial function has been assessed based on the endothelium-dependent vasodilator response, 13 and measurements of this response using digital pulse volume amplitude has emerged as a noninvasive, automated quantitative test for endothelial function. 14, 15 Based on the epidemiological association between pulmonary fibrosis and cardiovascular disease, we hypothesized that endothelial function would be more impaired among patients with pulmonary fibrosis and that the impairment would not be explained by the presence of classical cardiovascular risk factors. In the present study, we assessed endothelium-dependent vasodilator response in patients with pulmonary fibrosis using digital pulse amplitude tonometry (PAT) and evaluated the relationship between disease-related factors and endothelium-dependent vasodilator response.
Methods

Study subjects
We consecutively recruited 39 newly-diagnosed idiopathic chronic interstitial pneumonitis/fibrosis patients who visited Kyoto University Hospital. Patients diagnosed Page 7 / 25 as having any collagen vascular disease or vasculitis, and patients whose lung diseases were potentially caused by drug or occupational-environmental exposures were excluded. None of the patients had other pulmonary diseases or a history of cardiovascular events such as myocardial infarction or stroke, and none were receiving insulin, corticosteroids or supplementary oxygen therapy. IPF was diagnosed on the basis of the current official joint statement on IPF from the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society and Latin American Thoracic Association. 16 Age-, sex-and body mass index (BMI)-matched subjects without lung disease or any previous history of cardiovascular events were also recruited as controls. This study was approved by the Ethics Committee of Kyoto University and informed consent was obtained from all patients.
Arterial blood gas analysis, including arterial partial pressure of oxygen (PaO 2 ) and arterial partial pressure of carbon dioxide (PaCO 2 ), was performed while patients were breathing room air at rest in the supine position. The alveolar-arterial oxygen pressure difference (A-aDO 2 ) was calculated according to the standard formula, using a respiratory exchange ratio of 0.8. The degree of nocturnal hypoxemia was assessed by oxygen desaturation index (ODI) using a pulse oximeter (Pulsox-300i, Konica Minolta Inc., Osaka, Japan). ODI was calculated by dividing the total number of oxygen Page 8 / 25 desaturations by the total recording time, with desaturation defined as a decrease in SpO 2 to 4% or more below the baseline level. Six-minute walk testing was performed as recommended by ATS guidelines. 17 
Digital PAT
Endothelium-dependent vasodilator response was assessed by digital PAT in the fasting state, the principle of which has been described previously. 14, 15 Briefly, digital pulse amplitude was continuously recorded with the Endo-PAT 2000 device (Itamar Medical Inc., Caesarea, Israel) placed on the tip of each index finger and a blood pressure cuff was placed on one upper arm (study arm), while the contralateral arm served as a control (control arm). After a 5-min equilibration period, the cuff was inflated to 60 mmHg above the systolic blood pressure or 200 mmHg for 5-min and then deflated to induce reactive hyperemia. Pulse amplitude was recorded electronically in both fingers and analyzed by a computerized, automated algorithm that provided the ratio of the average amplitude over a 1-min time interval starting 1.5-min after cuff deflation divided by the average amplitude of a 2.5-min time period before cuff inflation.
The calculated ratio reflects the reactive hyperemia index (RHI), with a higher index indicating a higher flow-mediated hyperemic response. 18 Cytokine-specific antibody-coated beads were used for these experiments.
Beads were read on the Bio-Plex 200 suspension array system, and cytokine concentrations were automatically calculated with Bio-Plex Manager Software by a standard curve derived from a recombinant cytokine standard.
Pulmonary function tests
Pulmonary function tests were performed using a CHESTAC system (Chest M.I.
Inc., Tokyo, Japan). The diffusing capacity for carbon monoxide (DL CO ) was measured using the single-breath technique. Percent-predicted values were used for analyses.
Visual scoring of high-resolution computed tomography (HRCT)
Two independent observers (AK and TK) reviewed the three HRCT images taken at the level of the aortic arch, the carina and right inferior pulmonary venous confluence.
Each lobe of the lung was scored on a scale of 0-5 for the extents of ground glass opacity (ground-glass score) and fibrotic opacity (fibrosis score). 19 The scores for each lobe were averaged for the two observers for data analyses.
Statistics
All statistical analyses were performed using JMP version 9 software (SAS Institute, Cary, NC, USA). Continuous variables are expressed as mean±standard deviation (SD). 
Comparisons of variables between two groups were made by chi-square tests or
Results
Characteristics of patients and controls
The clinical characteristics of all subjects are summarized in Table 1 . Among 39 patients with idiopathic chronic interstitial pneumonitis/fibrosis, 11 had a typical usual interstitial pneumonia (UIP) pattern on HRCT scan. In the remaining 28 patients with HRCT results that were atypical for UIP, 12 patients underwent surgical lung biopsy: 6 had UIP, 1 had nonspecific interstitial pneumonia, and 5 did not meet ATS/ERS histopathologic criteria for a specific diagnosis of idiopathic interstitial pneumonias. 20 There was no statistically significant difference between groups with respect to sex, age, BMI, smoking, blood pressure, heart rate, ODI, prevalence of diabetes and usage rate of antihypertensive agents or statins. and DL CO were significantly lower in chronic interstitial pneumonitis/fibrosis patients than in control subjects (both p<0.001) but there were no significant differences in PaO 2 , PaCO 2 or A-aDO 2 . Although total cholesterol and triglycerides levels were similar in both groups, HDL levels were significantly lower and LDL levels were significantly Page 12 / 25 higher in idiopathic chronic interstitial pneumonitis/fibrosis patients than in control subjects (p=0.002 and 0.01, respectively). With regard to indices of diabetes, HbA1c and fasting glucose levels were comparable between groups.
RHI and its related factors
As shown in Figure 1 , RHI of idiopathic chronic interstitial pneumonitis/fibrosis patients was significantly lower than that of control subjects ( Next, we assessed whether significant relationships between RHI and disease severity are also observed in the homogeneous subgroup of IPF-confirmed patients.
Pulmonary function, arterial blood gas data, 6-minute walk distance and end-exercise oxygen saturation were not significantly different between IPF-confirmed patients and others. IPF-confirmed patients had less ground-glass and more fibrosis scores on HRCT (Supplementary Table 1 ). Among IPF-confirmed patients, RHI was significantly correlated with FVC (r=0.58, p=0.02), DL CO (r=0.64, p=0.006), A-aDO 2 (r=-0.50, p=0.04), end-exercise oxygen saturation (r=0.53, p=0.03) and HRCT fibrosis score (r=-0.54, p=0.03), but not with PaCO 2 (r=0.41, p=0.10), PaO 2 (r=0.40, p=0.12), 6-minute walk distance (r=0.36, p=0.16) or HRCT ground-glass score (r=-0.37, p=0.14)
(Supplementary Table 2 ). 
Relationships between RHI and circulating inflammatory biomarkers
Discussion
The present study demonstrated a significant impairment of digitally-recorded endothelium-dependent vasodilator response in patients with idiopathic chronic interstitial pneumonitis/fibrosis. This impairment was significantly related to DL CO , A-aDO 2 , 6-minute walk distance and end-exercise oxygen saturation, all of which were major physiologic indices for the severity of pulmonary fibrosis. Additionally, circulating levels of ICAM-1 and VCAM-1 correlated inversely with RHI. 21 In addition, diminished eNOS expression and NO release in chronic hypoxic human endothelial cells were also noted. 22 Thus, reduced exercise performance and systemic oxygen desaturation with exercise in pulmonary fibrosis can potentially elicit the impairment of endothelium-dependent vasodilator response via reduced expression of eNOS in the absence of other cardiovascular risk factors.
Dysfunctional endothelial cells can induce increased local production of endothelin-1, 23 angiotensin-II 24 and plasminogen activator inhibitor-1, 25 all of which are involved in the pathogenesis of pulmonary fibrosis. [26] [27] [28] Hence, conversely, local endothelial dysfunction in the lung could be associated with the development or progression of fibrosis, thereby possibly resulting in gas change derangement. Although The recruitment, adhesion and subsequent transendothelial migration of circulating leukocytes are important processes involved in atherosclerosis. 29 These processes are mediated by inflammatory cytokines and adhesion molecules, 10 the expression of which is upregulated in dysfunctional endothelial cells. 13 In our population, the concentrations of IL-1β, IL-6 and TNF-α were below detectable levels in more than half of the samples and circulating levels of CRP, fibrinogen and IL-8 were not significantly associated with RHI. These results suggest that systemic inflammation is less prominent and may play a minor role in the impairment of endothelium-dependent vasodilator response in patients with pulmonary fibrosis. However, we found significant and near significant negative correlations between circulating adhesion molecules and endothelial function, indicating the presence and association of dysfunction and inflammation in the vascular endothelium, although the magnitude might not be great.
Notably, while circulating levels of total cholesterol, triglycerides, HbA1c and Page 17 / 25 fasting glucose were similar, patients with chronic interstitial pneumonitis/fibrosis had significantly lower HDL levels and higher LDL levels than did control subjects.
Although these factors were not significantly related to RHI, they might contribute at least in part to the development of endothelial dysfunction. It is unclear whether impaired lipid metabolism is an outcome of pulmonary fibrosis itself or of comorbid conditions associated with pulmonary fibrosis. Local alterations in the lipid composition of bronchoalveolar lavage fluid were reported in animal models of bleomycin-induced pulmonary fibrosis, 30 as well as in patients with IPF. 31, 32 In addition, recent studies showed that obstructive sleep apnea was prevalent in patients with IPF 33 and that chronic intermittent hypoxia can cause circulating lipid levels to increase in relation to the severity of the hypoxic stimulus. 34 Thus, pulmonary fibrosis, comorbid conditions and metabolic alterations may be interrelated, but the underlying mechanisms remain to be elucidated and further studies are needed.
We should mention some of the limitations of the present study. Firstly, our cohort of patients was relatively heterogeneous because it also included some patients other than IPF or those who could not be diagnosed as IPF due to the lack of surgical lung biopsy. Although further studies with more samples of specific lung disease populations are necessary, RHI was also significantly correlated with disease severity including 
